GlassScriptPhysician profile
Cory Rafe White
NPI 1700973765
$412,687.13
in general payments reported to CMS, 2019-2025
47 companies · $39K in 2025
The $39K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $51K · 2021: $39K · 2022: $69K · 2023: $56K · 2024: $81K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166K · Travel and Lodging: $6,848 · Food and Beverage: $3,865 · Education: $64.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,000.00 |
| Travel and Lodging | $6,847.64 |
| Food and Beverage | $3,865.30 |
| Education | $64.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $363,238.96 | 2019-2025 | Mounjaro, Jardiance, Humulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38,370.10 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $4,449.01 | 2019-2023 | Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $601.12 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $522.41 | 2019-2023 | |
| Dexcom, INC. | $512.34 | 2019-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Corcept Therapeutics | $461.99 | 2019-2022 | |
| Amarin Pharma, INC. | $358.20 | 2019-2023 | |
| Novo Nordisk INC | $351.39 | 2019-2023 | Tresiba, Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $260.24 | 2019-2022 | |
| Antares Pharma, INC. | $257.81 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Xeris Pharmaceuticals, INC. | $250.90 | 2020-2022 | |
| Insulet Corporation | $245.05 | 2019-2023 | Omnipod |
| Amneal Pharmaceuticals LLC | $241.30 | 2019-2022 | |
| Ibsa Pharma INC. | $215.25 | 2019-2023 | Tirosint, Licart |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.